🔬Deep Research
ALNY — Alnylam Pharmaceuticals Inc · catalysts, narrative & risks
Overview (point-in-time: 2026-11-15)
Alnylam Pharmaceuticals (Nasdaq: ALNY) is a Cambridge, MA–based RNAi therapeutics company with six approved medicines and a broad early-to-late pipeline [3], [8], [15]. Over the trailing twelve months the stock has been highly volatile, and the recent driver of attention is the quality of demand for its flagship drug AMVUTTRA (vutrisiran), plus a steady stream of clinical readouts. Below is a synthesis of the last ~1–3 months, cross-checked across sources, with notable inconsistencies flagged.
Recent catalysts (Aug–Nov 2026)
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →